Sera Prognostics (SERA) Expected to Announce Quarterly Earnings on Wednesday

Posted by Defense World Staff on Mar 12th, 2025

Sera Prognostics (NASDAQ:SERA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect Sera Prognostics to post earnings of ($0.23) per share for the quarter.

Sera Prognostics Stock Up 1.9 %

Shares of NASDAQ SERA opened at $4.22 on Wednesday. The business’s 50 day moving average price is $5.54 and its 200 day moving average price is $6.73. The firm has a market cap of $142.52 million, a P/E ratio of -4.26 and a beta of 0.89. Sera Prognostics has a 52 week low of $3.84 and a 52 week high of $12.36.

Insider Buying and Selling at Sera Prognostics

In other news, Director Joshua Phillips sold 12,163 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.39, for a total value of $77,721.57. Following the sale, the director now owns 2 shares in the company, valued at $12.78. This represents a 99.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Benjamin Jackson sold 7,912 shares of Sera Prognostics stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $6.38, for a total value of $50,478.56. Following the transaction, the general counsel now owns 120,561 shares of the company’s stock, valued at approximately $769,179.18. This represents a 6.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,877 shares of company stock worth $480,677. Company insiders own 15.80% of the company’s stock.

Sera Prognostics Company Profile

(Get Free Report)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.